Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.

摘要: Abstract Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's worldwide. Although patient outcomes have significantly improved to a greater than 40% cure rate by combinatorial cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which widely used, resistance CHOP regimen continues pose problem in managing or curing DLBCL. While it promotes malignancy chemo-resistance certain types cancer, Annexin A5 negatively correlated with those other cancers, including In present study, we explored effects on DLBCL cell invasion chemoresistance CHOP. Stable overexpression knockdown were performed Toledo Pfeiffer human lines. Overexpression both lines decreased invasion, matrix metalloproteinase-9 (MMP-9) expression/activity, phosphatidylinositol 3-kinase (PI3K) activity/Akt phosphorylation, survival against CHOP-induced apoptosis. On hand, markedly increased MMP-9 PI3K apoptosis lines, was abolished selective inhibitor BKM120. conclusion, our study provides first vitro evidence that inhibits through PI3K-dependent mechanism; new insight not only into biological function A5, but also molecular mechanisms underlying progression chemoresistance.